Detection of 90Y Extravasation by Bremsstrahlung Imaging for Patients Undergoing 90Y-Ibritumomab Tiuxetan Therapy
نویسندگان
چکیده
منابع مشابه
Detection of 90Y extravasation by bremsstrahlung imaging for patients undergoing 90Y-ibritumomab tiuxetan therapy.
UNLABELLED Extravasation of therapeutic (90)Y-ibritumomab tiuxetan can cause significant injury. Detection of extravasated (90)Y using a γ-camera for patients undergoing (90)Y-ibritumomab tiuxetan therapy is a challenge because of the inherently low efficiency of bremsstrahlung imaging and the interference of prompt and scattered photons from (111)In that are still present in the body at the ti...
متن کاملAccurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan.
UNLABELLED This investigation examined the accuracy of dose calibrator activity measurement of the beta-emitting radiopharmaceutical (90)Y-ibritumomab tiuxetan. METHODS Five different facilities independently measured (90)Y in a 10-mL syringe geometry with 30 dose calibrator models from 3 different manufacturers. The activities ranged from 81.4 MBq (2.2 mCi) to 1,406 MBq (38 mCi) over the vol...
متن کاملPredicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab.
UNLABELLED This study aimed at identifying clinical factors for predicting hematologic toxicity after radioimmunotherapy with (90)Y-ibritumomab tiuxetan or (131)I-tositumomab in clinical practice. METHODS Hematologic data were available from 14 non-Hodgkin lymphoma patients treated with (90)Y-ibritumomab tiuxetan and 18 who received (131)I-tositumomab. The percentage baseline at nadir and 4 w...
متن کاملQuantification of dose nonuniformities by voxel-based dosimetry in patients receiving 90Y-ibritumomab-tiuxetan.
UNLABELLED Abstract Objective: To assess the impact of nonuniform dose distribution within lesions and tumor-involved organs of patients receiving Zevalin(®), and to discuss possible implications of equivalent uniform biological effective doses (EU-BED) on treatment efficacy and toxicity. MATLAB™ -based software for voxel-based dosimetry was adopted for this purpose. METHODS Eleven lesions fr...
متن کاملEANM procedure guideline of radio-immunotherapy for B-cell lymphoma with 90Y-radiolabeled ibritumomab tiuxetan (Zevalin®)
EMEA has approved Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular Bcell non-Hodgkin ́s lymphoma (NHL) in January 2004. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy-, the Oncologyand the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Nuclear Medicine Technology
سال: 2010
ISSN: 0091-4916
DOI: 10.2967/jnmt.110.077354